September 27, 2012

DSN caught up with Dave Dimas — program director of engineering, sciences and information technology at the University of California, Irvine Extension — to discuss the role predictive analytics can play in health care, as well as a new certificate program on how to best translate that consumer data into action plans.

September 21, 2012

DSN sat down with Judy Blatman, SVP communications for the Council for Responsible Nutrition, to get the details on the launch of the organization's "Life…Supplemented" resource app for iPhones and iPads.

September 21, 2012

DSN sat down with Jeff Weidauer, Vestcom International VP marketing and strategy, for some insights on who the millennial is, and when it comes to shopping, what her expectations are.

August 27, 2012

AccentHealth’s Andrew Schulman, VP marketing, recently sat down with DSN to talk about a new regular DSN feature debuting in this issue called “Patient Views,” and how this series of surveys can help inform pharmacy operators and healthcare suppliers alike.

July 18, 2012

As part of the Executive Viewpoint Series, DSN talked to Dan Mack — DSN expert blogger, EVP strategic sales at The Swanson Group and managing director of Mack Elevation Forum — discusses his unique perspective on what suppliers should focus on when engaging with retailers and what "blind spots" they should be wary of.

July 11, 2012

DSN talked to Cardinal Health SVP independent sales Steve Lawrence about the big news from Cardinal’s 2012 Retail Business Conference, including a best practices competition for its customers, its Women in Pharmacy program and Cardinal’s joint outreach program with the Ohio State University College of Pharmacy aimed at preventing prescription drug abuse.

May 21, 2012

Retail pharmacy veteran Frank Scorpiniti officially assumed the role of CEO of Rexall Pharma Plus in February. Now that he’s settled in North of the Border, Scorpiniti talked with Drug Store News about his new role and his insights on the Canadian retail pharmacy market.

April 23, 2012

In part 3, VP health and wellness operations and compliance Jim Langman and director of business development Angie Muldoon discuss how Sam's Club's clinical offerings — pharmacy, optical and hearing aid centers — and its health screenings and new magazine align with the retailer's wellness platform.

March 21, 2012

Earlier this month, Walgreens announced that immunization records would be sent directly from its more than 7,800 Walgreens and Duane Reade stores and 350 Take Care Clinics to primary care providers over Surescripts’ electronic prescribing network using Surescripts’ Clinical Interoperability services. And later this year, the company plans to share immunization data with local and state public health agencies, and share Take Care Clinic patient summaries with primary care providers. Drug Store News recently had the opportunity to speak with Surescripts president and CEO Harry Totonis about the new service.

March 5, 2012

Radio Health Journal's Reed Pence talks with DSN editor in chief Rob Eder; Walgreens president of pharmacy, health and wellness Kermit Crawford; Express Scripts senior director of public affairs Brian Henry; and former Walgreens pharmacy customer Virginia Greathouse about the causes and impact of the Walgreens-ESI dispute.

February 28, 2012

Walgreens Specialty Pharmacy in late February released data showing that both patients and their health plans can realize savings of up to 60% on the cost of infused specialty medications by choosing alternate treatment sites, such as the ones fielded by Walgreens. DSN caught up with Michael Einodshofer, director of utilization management at Walgreens Specialty Pharmacy, to discuss the potential cost-reduction impact savings it can have on employers and payers.

February 28, 2012

As part of its Executive Retailer Viewpoint series, DSN sat down with Chuck Wilson, VP pharmacy operations at Health Mart, at DSN's Industry Issues Summit to discuss opportunities for community pharmacy to improve patient outcomes.

February 17, 2012

As part of its Executive Retailer Viewpoint series, DSN sat down with Mike Cantrell, president at Good Neighbor Pharmacies, at DSN's Industry Issues Summit to discuss technology and the evolution of pharmacy care.

February 1, 2012

As part of DSN's Executive Retailer Viewpoint series, DSN sat down with Jason Reiser, VP health and wellness, ops/compliance at Sam's Club, at DSN's Industry Issues Summit to discuss how to better engage customers and the impact of the economy on business in 2012.

January 18, 2012

In an effort to tap into the minds of some of the industry's top executives, Drug Store News recently sat down and talked with some of these leaders in a multipart executive viewpoint video series.

January 3, 2012

On Sunday, Jan. 1, Walgreens' contract with Express Scripts expired, and millions of Walgreens customers covered by ESI were forced to either move their pharmacy business to another pharmacy in the Express Script network or come up with some other way to stick with Walgreens. DSN editor Rob Eder on Tuesday interviewed Walgreens president and CEO Greg Wasson on what the company is doing to hold on to those customers and to appeal to payers, and what the potential ESI-Medco deal could mean.

November 25, 2015

Aurobindo’s sildenafil tablets are a generic version of Pfizer’s Revatio, which treats pulmonary arterial hypertension. 

November 25, 2015

Despite pre-exposure prophylaxis pills’ efficacy in preventing HIV that’s transmitted sexually or through use of injected drugs, only one-in-three primary care physicians and nurses have heard of it. 

November 25, 2015

Novartis’ Fluad is a trivalent flu vaccine that contains the adjuvant MF59, an emulsion of squalene oil in water, and is aimed at improving immune response among patients 65 years of age and older. 

November 25, 2015

The drug, according to IMS Health data for the 12 months eneding Sept. 2015, had combined brand and generic sales of $457 million. 

November 24, 2015

The Medicare savings that the American College of Physicans says could be saved by focusing on generics is estimated to total $1.4 billion. 

November 24, 2015

Eli Lilly and Co.’s Petrazza in a trial extended the lives of patients who took the drug in combination with two forms of chemotherapy to 11.5 months. 

November 24, 2015

Mylan has introduced its generic of Jazz Pharmaceuticals’ schizophrenia treatment. 

November 24, 2015

Following Monday’s announcement that Pfizer would be merging with Ireland-based company Allergan, some analysts are predicting that Pfizer would split the combined company following the $160 billion deal, Reuters reported. According to the report, the split would likely divide the company’s established products (i.e., generics) unit and its innovative medicines unit, composed of drugs that are still patent-protected. (Reuters)